In vitro studies suggest that the female sex steroid hormones [estrogen (E) and progesterone (P)] can affect the myoelectric and mechanical activity of colonic smooth muscle. The present study was designed to examine the influence of the hormones on colonic transit in vivo. Transit was assessed by quantifying the distribution within the colon of a radiolabeled marker (0.5 microCi Na251CrO4), using the geometric center method of analysis. Studies were performed with adult male rats and the following groups of female rats: nonpregnant, ovariectomized, ovariectomy plus hormone pretreatment (100 micrograms X kg-1 X day-1 E + 2.5 mg X kg-1 X day-1 P for 4 days), and pregnant (day 18). Hormone-pretreated animals were studied 24 h following the fourth injection. The data can be summarized as follows. 1) Colonic transit was affected by the timing of the estrus cycle. Rats determined to be in proestrus-estrus had a geometric center value (1.97 +/- 0.50) significantly less than that of metestrus-diestrus animals (4.25 +/- 0.57). 2) Ovariectomy eliminated the biphasic transit pattern observed in estrus-cycling females and resulted in a geometric center value (4.19 +/- 0.17) comparable with that of the metestrus-diestrus animals. 3) E + P pretreatment of ovariectomized rats resulted in a significant decrease in the geometric center (1.94 +/- 0.19) compared with the untreated ovariectomized rats. 4) The geometric center value in pregnant animals (2.22 +/- 0.20) closely resembled the transit data for proestrus-estrus animals and hormone-pretreated animals.(ABSTRACT TRUNCATED AT 250 WORDS)
The aims of this study were to determine regional differences and the mechanism of gastric contractile effects of erythromycin. Rabbit gastric circular muscle strips were studied in vitro. The threshold dose for erythromycin was significantly less and the maximum contraction greater in the antrum (1 microM and 0.9 +/- 0.3 kg/cm2) than in the fundus (10 microM and 0.3 +/- 0.1 kg/cm2). Erythromycin-induced antral contractions were decreased by motilin tachyphylaxis but unaffected by tetrodotoxin, atropine, hexamethonium, or ondansetron. At a subthreshold dose (0.1 microM), erythromycin increased the frequency, but not the amplitude, of bethanechol (10 +/- 3%)-and substance P-induced (13 +/- 5%) phasic antral contractions. This chronotropic effect was inhibited with tetrodotoxin, atropine, or motilin tachyphylaxis. Erythromycin (10 microM) and motilin (1 microM) enhanced the amplitude of substance P-induced tonic fundic contractions by 38 and 32%, respectively, without effect on bethanechol-induced contractions. In summary, erythromycin contracts antral muscle more potently and forcefully than fundic muscle. Erythromycin increases antral contractility by two mechanisms: an inotropic effect acting on smooth muscle motilin receptors, and, at lower doses, a cholinergic chronotropic effect mediated through neuronal motilin receptors.
In a factorially designed experiment (N = 321), 0, 800 or 1600 I.U. pregnant mare serum gonadotrophin (PMSG) were administered in combination with 0, 12 or 18 mg follicle stimulating hormone (FSH-P) to superovulate Merino ewes in autumn and spring. A moderate dose of PMSG (800 I.U.) in conjunction with 12 or 18 mg FSH-P increased the ovulation rate above that observed when FSH-P was used alone. This was accomplished by (i) increasing the proportion of ewes that exhibited a superovulatory response (greater than 3 corpora lutea (CL) or persistent large follicles (LF): 69/70 (99%) v. 55/74 (74%), P less than 0.001), and (ii) in those ewes that exhibited a superovulatory response, by an additive effect of exogenous gonadotrophin (14.8 +/- 0.9 CL (69) v. 11.3 +/- 0.9 CL (55), P less than 0.01) without increasing the incidence of LF. The use of 1600 I.U. PMSG in conjunction with 12 or 18 mg FSH-P was characterized by an increase in the number of LF and, in comparison with 800 I.U. PMSG, a reduction in ovulation rate. Season had no effect on the numbers of CL, but total ovarian response (CL + LF) was higher in autumn than in spring (P less than 0.01), because of a greater incidence of LF (P less than 0.001). The proportion of ewes with regressed CL was higher in autumn than in spring (53/143 (37%) v. 32/156 (21%), P less than 0.01), and increased with increased dose of gonadotrophin. Furthermore, a nutritional component to the incidence of ewes with regressed CL was suggested by the observation that the mean concentration of plasma glucose was higher for ewes with normal CL than for ewes with regressed CL (P less than 0.05). Rates of ova or embryo recovery, fertilization and embryo development generally declined with an increase in the incidence of LF as a result of increases in the dose of gonadotrophin and season of administration.
Administration of gonadotrophin releasing hormone (GnRH) 24 h after sponge withdrawal did not affect the numbers of corpora lutea (CL) or persistent large follicles (LF) in ewes superovulated with 400 I.U. pregnant mare serum gonadotrophin and 12 mg follicle stimulating hormone in spring (11.6 +/- 0.9 v. 13.0 +/- 0.9 CL and 0.8 +/- 0.9 v. 0.9 +/- 0.3 LF, for +GnRH and -GnRH ewes, respectively). However, it did increase the ovulatory response of ewes superovulated in autumn (15.8 +/- 1.2 v. 11.8 +/- 1.1 CL). The incidence of ewes with prematurely regressed CL was also greater in autumn than in spring (21/89 v. 5/88). Supplementary feeding with lupin grain in autumn had no effect on numbers of CL but did increase the incidence of ewes with LF (18/48 v. 7/46) and caused a marked reduction in the incidence of ewes with regressed CL (1/44 v. 20/45). For ewes treated in autumn, there were no effects of lupin supplementation or GnRH administration on peak oestradiol-17 beta (E2) or peak luteinizing hormone (LH) levels. However, when peak E2 concentrations in the plasma were adjusted for numbers of preovulatory follicles, higher concentrations were observed for ewes in the +lupin/-GnRH group (12.4 +/- 2.9 pg mL-1) than in other treatment groups (range 4.3 +/- 0.4 to 5.7 +/- 0.3 pg mL-1). Moreover, the time of the LH peak was advanced by both lupin supplementation and GnRH treatment.(ABSTRACT TRUNCATED AT 250 WORDS)
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.